LncRNA GAS5 knockdown attenuated HFD-induced hepatic steatosis, and this attenuation was reversed by the miR-29a-3p inhibitor; thereby providing vital evidence to establish the function of lncRNA GAS5 in the pathogenesis of NAFLD and its progression by targeting miR-29a-3p in vivo [14]. The gene discussed is GAS5; the disease is metabolic dysfunction-associated steatotic liver disease.